Ambea AB has announced the successful completion of its public offer to acquire Humana AB, a move that will significantly reshape the healthcare services landscape in Sweden. With approximately 98% of Humana's shares now under its control, Ambea is poised to enhance its service offerings and market presence. This acquisition underscores the ongoing trend of consolidation within the healthcare sector as companies strive to improve their competitive edge.
On June 29, 2026, Ambea initiated a recommended public offer to Humana's shareholders, proposing a combination of cash and shares as compensation. The offer included SEK 20 in cash for each share, along with 0.305 shares of Ambea and a contingent value right (CVR) instrument. The initial acceptance period saw a strong response, with shareholders tendering over 90% of outstanding shares by October 1, 2026.
According to the recent SEC filing dated October 20, 2026, the total number of shares accepted during the extended period reached 46,564,851, equating to 97.99% of Humana's outstanding shares. Ambea has stated that it will not extend the acceptance period any further, effectively closing the offer.
In conjunction with the acquisition, Ambea's Board of Directors has approved a new share issue to facilitate the delivery of shares as part of the consideration for Humana's shareholders. This move will increase Ambea's share capital by approximately SEK 30,749, further integrating Humana into its operations.
Settlement and delivery of the cash and share considerations for the shares tendered during the extended acceptance period are expected to commence on or around October 21, 2026. Additionally, Ambea has initiated compulsory redemption proceedings to acquire all remaining shares in Humana, indicating a commitment to full ownership.
The acquisition of Humana is a strategic maneuver for Ambea, as it seeks to strengthen its position in the healthcare market. The Board of Directors of Humana has also applied for the delisting of its shares from Nasdaq Stockholm, with the last trading day scheduled for October 27, 2026.
This acquisition not only marks a significant milestone for Ambea but also reflects broader trends in the healthcare sector, where companies are increasingly consolidating to enhance service offerings and operational efficiencies. As Ambea integrates Humana into its operations, it may set a precedent that encourages other players in the industry to pursue similar strategies.
Ambea has engaged DNB Carnegie Investment Bank AB as its financial advisor for this transaction, with legal support from Advokatfirman Vinge KB and Milbank LLP. The completion of this acquisition will likely have lasting implications for the competitive landscape of healthcare services in Sweden.
As the healthcare sector continues to evolve, stakeholders will be watching closely to see how Ambea leverages this acquisition to drive growth and innovation in its service offerings.